Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.65 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.65 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.65 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.61 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385995 | 1.00 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL385978 | 1.00 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL386248 | 1.00 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL383519 | 1.00 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL385481 | 1.00 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL1477766 | 1.00 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL207207 | 1.00 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL11995515 | 1.00 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL385929 | 0.98 | PRKCA (0.77) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL3918449 | 0.97 | PRKCA (0.85) | PRKCAALDH1A1LMNAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 565 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815644-B2 | Paper feed roller | SUMITOMO RIKO COMPANY LIMITED (JP) | 2017-11-14 | — | — | US | claimed |
| US-20160130098-A1 | PAPER FEED ROLLER | SUMITOMO RIKO COMPANY LIMITED (JP) | 2016-05-12 | — | — | US | claimed |
| EP-1541125-A1 | Spreadable compositions for topical use, a process of making same and uses thereof | AGIS INDUSTRIES (1983) LTD (IL) | 2005-06-15 | — | — | EP | claimed |
| US-20050123575-A1 | Spreadable compositions for topical use, an improved process of making same and methods of using same | PERRIGO ISRAEL PHARMACEUTICALS LTD. (IL) | 2005-06-09 | — | — | US | claimed |
| JP-10195306-A | — | — | None | — | — | JP | disclosed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | disclosed |
| EP-4081215-B1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4727923-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260102428-A1 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS | UAB RES FOUND (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260098012-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12594265-B2 | Methods and compositions for inhibition of STAT3 | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-07 | — | — | US | disclosed |
| US-12569503-B2 | Methods and compositions for substituted axially-chiral cannabinol analogs | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-4148893-A | SUGAR ESTER AND DIALKYL SULFOXIDE ENHANCE PENETRATION THROUGH SKIN | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4148924-A | Dermatological compositions | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4130667-A | A SUCROSE ESTER AND A PHOSPHINE OXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
| US-4130643-A | STEROID, SUCROSE ESTER, SULFOXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
| US-4046886-A | SUGAR ESTER, PHOSPHINE OXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1977-09-06 | — | — | US | disclosed |
| US-3953599-A | ANTICHOLINERGIC SCOPOLAMINE ESTERS | THE PROCTER & GAMBLE COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
| US-3952099-A | MICROBIOCIDE, SUGAR ESTER, SULFOXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1976-04-20 | — | — | US | disclosed |
| US-3943248-A | Methods of treating burns using colophony containing preparations | SHULMAN MAX J | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569503-B2 | Methods and compositions for substituted axially-chiral cannabinol analogs | OPRD1, OPRM1, OPRK1 | PRKCA 1852/4885ALDH1A1 1782/4885LMNA 3084/4885 |
| US-20260102428-A1 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS | SOD1, CUTA, SOD3 | PRKCA 3288/4885ALDH1A1 2143/4885LMNA 4620/4885 |
| US-12594265-B2 | Methods and compositions for inhibition of STAT3 | STAT3, JAK2, MALT1 | PRKCA 494/4885ALDH1A1 2734/4885LMNA 3996/4885 |
| US-20260098012-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | CD47, SLC11A2, G6PD | PRKCA 543/4885ALDH1A1 873/4885LMNA 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.